Discovery of novel Henipavirus inhibitors
Discovery of novel Henipavirus inhibitors
批准号:
10514154
负责人:
Thomas William Geisbert
金额:
$529.18万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-16 至 2025-04-30
关键词:
2019-nCoVAfrican Green MonkeyAnimalsAntiviral AgentsAntiviral TherapyAutomationBangladeshBiochemicalBiological AssayBiologyCase Fatality RatesCellsChemicalsCommunicable DiseasesContainmentCoronavirusCountryCrystallizationDengueDengue VirusDevelopmentDiseaseDisease OutbreaksDrug DesignDrug TargetingDrug resistanceEncephalitisEvaluationFamilyFlavivirusGenerationsGoalsHamstersHendra VirusHenipavirusHumanIn VitroIndiaInfectionLeadLuciferasesMalaysiaMapsMedicalMiniaturizationModelingModernizationMutationNipah VirusParamyxovirusPathogenicityPersonsPharmaceutical ChemistryPhase I/II Clinical TrialPhenotypePhilippinesProteinsRecombinantsResearchRodentServicesStructureStructure-Activity RelationshipSystemTechnologyTestingTexasTherapeuticTriageUniversitiesVaccinesVariantViralViral GenesVirusanimal efficacybasebiophysical techniquesbiosafety level 4 facilityclinical candidatecombatcytotoxicitydrug discoverydrug resistant virusefficacy studyhigh throughput screeninghuman pathogenin vivoin vivo Modelinhibitorlead optimizationmanmembernovelpandemic diseasepandemic preparednesspharmacokinetics and pharmacodynamicspre-clinicalpreclinical developmentprotective efficacyrespiratoryrespiratory pathogenreverse geneticssafety studyscreeningsmall moleculetooltransmission processvirologywhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT 3 – ABSTRACT
The goal of this project is to discover novel henipavirus inhibitors. Henipavirus is a deadly airborne respiratory
pathogen that are under-researched and poorly understood. Antiviral therapy is urgently needed for
henipaviruses for pandemic preparedness. We will achieve the goal by pursuing three aims. (i) Screen and
identify novel compounds for Nipah and/or Hendra virus inhibition. Since Nipah and Hendra viruses should be
handled at BSL4, it is challenging to perform high-throughput screen at high containment. To overcome this
bottleneck, we will use a BSL2 Cedar henipavirus as a surrogate system for antiviral screen. Hits identified from
the Cedar henipavirus assay will be validated in Hendra and Nipah viruses at the BSL4 facility. (ii) Develop tool
compounds, determine target protein, and optimize molecules. (iii) Evaluate lead compounds in relevant in vitro
and in vivo models and select Development Candidate for IND-enabling studies. The proposed cell-based
approach may discover novel antiviral targets that may not be tractable for target-based antiviral approach.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of novel Henipavirus inhibitors
-
批准号:10845863
-
项目类别:
-
资助金额:$231.77万
-
财政年份:2022
-
负责人:Thomas William Geisbert
-
依托单位:
Preclinical development of a vaccine for Nipah virus
-
批准号:10214949
-
项目类别:
-
资助金额:$141.6万
-
财政年份:2021
-
负责人:Thomas William Geisbert
-
依托单位:
Preclinical development of a vaccine for Nipah virus
-
批准号:10369731
-
项目类别:
-
资助金额:$117.98万
-
财政年份:2021
-
负责人:Thomas William Geisbert
-
依托单位:
Preclinical development of a vaccine for Nipah virus
-
批准号:10576335
-
项目类别:
-
资助金额:$115.9万
-
财政年份:2021
-
负责人:Thomas William Geisbert
-
依托单位:
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine
-
批准号:10217000
-
项目类别:
-
资助金额:$64.23万
-
财政年份:2020
-
负责人:Thomas William Geisbert
-
依托单位:
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine
-
批准号:10655324
-
项目类别:
-
资助金额:$73.99万
-
财政年份:2020
-
负责人:Thomas William Geisbert
-
依托单位:
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine
-
批准号:10440280
-
项目类别:
-
资助金额:$74.0万
-
财政年份:2020
-
负责人:Thomas William Geisbert
-
依托单位:
Core C - The University of Texas Medical Branch at Galveston
-
批准号:10362729
-
项目类别:
-
资助金额:$80.23万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections
-
批准号:9889877
-
项目类别:
-
资助金额:$733.94万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections
-
批准号:10356834
-
项目类别:
-
资助金额:$704.32万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
Administrative Core (Core A)
-
批准号:10564148
-
项目类别:
-
资助金额:$20.62万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
BSL-4 Evaluation Core (Core B)
-
批准号:10564149
-
项目类别:
-
资助金额:$283.42万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
Administrative Core (Core A)
-
批准号:10576277
-
项目类别:
-
资助金额:$20.25万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for Filoviruses
-
批准号:10576281
-
项目类别:
-
资助金额:$72.36万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for Filoviruses
-
批准号:10564152
-
项目类别:
-
资助金额:$66.39万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
Core C - The University of Texas Medical Branch at Galveston
-
批准号:10581495
-
项目类别:
-
资助金额:$253.87万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections
-
批准号:10576276
-
项目类别:
-
资助金额:$704.32万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
BSL-4 Evaluation Core (Core B)
-
批准号:10576278
-
项目类别:
-
资助金额:$289.09万
-
财政年份:2019
-
负责人:Thomas William Geisbert
-
依托单位:
Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever
-
批准号:9363104
-
项目类别:
-
资助金额:$134.53万
-
财政年份:2017
-
负责人:Thomas William Geisbert
-
依托单位:
Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever
-
批准号:10179308
-
项目类别:
-
资助金额:$110.47万
-
财政年份:2017
-
负责人:Thomas William Geisbert
-
依托单位:
海外基金